SRTA — Strata Critical Medical, Inc.

Summary of Strata Critical Medical, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $66.8 million, up from $36.4 million year-over-year, driven by a 35.3% organic growth in logistics to $49.2 million.
• Full-Year 2025 Revenue: $197.1 million, exceeding guidance.
• Adjusted EBITDA: $7.0 million in Q4 2025, significantly up from $1.1 million in Q4 2024.
• Gross Profit: Increased 90% to $14.4 million in Q4 2025, with a gross margin of 21.6%.
• Operating Cash Flow: Negative $8.3 million, impacted by nonrecurring items and working capital delays.
• Cash Position: Approximately $61 million in cash and short-term investments, with no debt.

2. Strategic Updates and Business Highlights

• Acquisition Strategy: Continued focus on acquiring smaller businesses to enhance growth and geographic reach, with a goal of maintaining at least 30% annualized adjusted EBITDA growth.
• Regulatory Positioning: Positive regulatory developments, particularly regarding DCD (donation after circulatory death) donors, align with the company’s capabilities and market position.
• Operational Changes: Expanded leadership with Dr. Scott Silvestri appointed as Chief Medical Officer, enhancing clinical capabilities.
• Logistics Growth: Strong performance in logistics, with over 40% of growth attributed to Keystone's legacy customers.
• Aircraft Fleet: Ended the year with approximately 30 aircraft; one aircraft was parted out due to corrosion, resulting in a book loss of $1.7 million.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $260–$275 million from $255–$270 million.
• Adjusted EBITDA Guidance: Increased to $29–$33 million from $28–$32 million.
• Free Cash Flow Guidance: Reiterated at $15–$22 million.
• Q1 2026 Expectations: Anticipated modest sequential revenue decline due to seasonal factors and weather impacts, but expected recovery in Q2 and beyond.

4. Bad News, Challenges, or Points of Concern

• Operating Cash Flow: Negative cash flow in Q4 due to nonrecurring costs and working capital issues, which may affect liquidity in the short term.
• Weather Impact: Severe weather in the Northeast caused operational disruptions, potentially affecting Q1 performance.
• Regulatory Scrutiny: Ongoing scrutiny in the transplant sector could pose challenges, although the company believes it is well-positioned to adapt.
• Cost Pressures: Rising fuel prices may impact customer costs, although these are typically passed through to customers.

5. Notable Q&A Insights

• Regulatory Policy: Continuous distribution policy for organ allocation is still a goal; however, its implementation timeline remains uncertain due to regulatory focus on pressing issues.
• Acquisition Pipeline: The company plans to announce acquisitions as they close, focusing on enhancing scale and service offerings.
• Radiopharmaceuticals: Currently piloting radiopharmaceutical transport but not planning immediate acquisitions in this area.
• Customer Acquisition: New customer wins are encouraging, with an integrated service model resonating well in the market.

Overall, Strata Critical Medical, Inc. reported strong financial performance in Q4 2025, driven by organic growth and strategic acquisitions, while also raising guidance for 2026. However, challenges related to cash flow, weather impacts, and regulatory scrutiny remain areas of concern.